Gen Z might reject your job offer if it doesn’t come with Ozempic
Ozempic has apparently made it all the way into job negotiations, which feel very 2026. Younger workers are still asking about pay, health insurance and how many days they can be a person out of the office. Now a growing number are also looking at whether an employer will cover GLP-1 drugs like Ozempic or Wegovy, because of course a drug that can cost a fortune would end up in the same mental bucket as PTO and dental.
According to a new ZipHealth survey of 1,004 US workers conducted in March 2026, 47% of Gen Z said GLP-1 coverage would influence their choice between two similar jobs. Nine percent said they would take a pay cut to work somewhere that offered that coverage. Across all workers, 51% said GLP-1 drug coverage should be a standard benefit, and 54% said they would give up at least one workplace fringe benefit to get employer-covered treatment. Thirteen percent said they would sacrifice a full week of PTO. Which is kind of sad, but also completely believable.
That state says a few things at once. First, these drugs have moved out of celebrity gossip and into mainstream adult decision-making. Second, the health care system in this country remains such a disaster that people trade access to a prescription drug against vacation time. Third, employers love to brag about snack walls and wellness initiatives, right up until workers want benefits that cost real money.
Some Gen Z workers will want Ozempic included in the job offer
The study also touches on the part that companies love to fumble, which is basic human sensitivity. Among Gen Z workers, 58% said they felt uncomfortable discussing weight management goals with HR, 53% felt uncomfortable disclosing GLP-1 use, and 38% had kept their weight loss efforts private at work. Across all workers, only 1 in 10 said they would disclose the use of GLP-1 to a new employer. Seventeen percent said they had felt judged, stigmatized or excluded at work because of their weight or weight loss efforts. Another 17% worried that GLP-1 use might change how managers or colleagues viewed their discipline or professionalism.
This is the part employers will probably have to sit with for a minute. Workers want access, but many still don’t trust the office enough to talk clearly about why. And honestly, can you blame them? Weight is still one of those subjects people claim to handle with compassion until they’re in a conference room where a person’s “discipline” is being scrutinized just based on their body type.
The survey is about benefits, but the real issue is access. Specifically, who gets it, who stays silent about needing it, and why so much of America’s health care still runs through your payroll department.
